LibiGel testosterone: Phase III completed

BioSante stopped a double-blind, placebo-controlled, international Phase III safety trial of transdermal LibiGel because the company believes it has "adequate safety data" to support an NDA submission for LibiGel to treat HSDD in menopausal women. The

Read the full 368 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE